Neurolex is being transitioned to a new system and is currently not accepting new additions. If you have additions or questions please contact us at [email protected], or submit an issue to the github issue tracker at


From NeuroLex

Jump to: navigation, search
Category:Resource:Alzheimers Disease Cooperative Study
Abbrev ADCS  +
Address 9500 Gilman Drive M/C 0949  +, La Jolla  +, CA 92093-0949  +, Region: USA  +
Comment Sample type: Image, Tissue, Blood, Plasma, DNA, Urine, Cerebral Spinal Fluid
CurationStatus uncurated  +
DefiningCitation  +
Definition A major initiative for Alzheimer's disease A major initiative for Alzheimer's disease (AD) clinical studies in the Federal government addressing treatments for both cognitive and behavioral symptoms. This is part of the NIA Neuroscience and Neuropsychology of Aging Program's effort to facilitate the discovery, development and testing of new drugs for the treatment of AD and also is part of the Alzheimer's Disease Prevention Initiative.<br /> The ADCS was developed in response to a perceived need to advance research in the development of drugs that might be useful for treating patients with Alzheimer's disease (AD), particularly drugs that might not be developed by industry. As such, the mandate of the ADCS is to: * Improve cognition, slow the rate of decline, or delay the appearance of AD. * Develop studies for promising agents designed to ameliorate behavioral symptoms. * Design new instruments for use in clinical studies. * Conceive of novel and innovative approaches to clinical study design and AD clinical study analysis. * Expand the range of patients studied in AD studies. * Enhance the recruitment of minority groups into AD studies. The ADCS focuses on evaluating compounds that will benefit the general good of AD patients. This includes the testing of agents that lack patent protection, are under patent protection but are already marketed for other indications but where the agent may be useful in treating AD, and are novel compounds developed by individuals, academic institutions and drug discovery units. Since 1991, the ADCS has initiated 30 research studies (23 drug studies and 7 instrument development protocols) with the majority of studies carried out at 20 or more AD research centers. The number of participants enrolled in these Phase I to Phase III research studies have ranged from 9 to 800 people per study. ADCS studies have generated numerous publications. Some key highlights of ADCS activities include: * Development of AD centers capable of carrying out AD studies in the United States and Canada. * Establishment of a robust Administrative, Data, Operations and Medical Cores based in San Diego. * Development of important new instruments including the first Activities of Daily Living Scale specifically developed for AD patients, and standardization of the Clinical Global Impression of Change. * Standardization and development of worksheets for the use of the Clinical Dementia Rating Scale. * Completion of a protocol testing vitamin E and selegiline which demonstrated that both agents can cause approximately a six month delay in the time for moderately advanced AD patients to reach important endpoints including progression from moderate to severe dementia, loss of basic activities of daily living, institutionalization, and death. * Development of the concept of mild cognitive impairment as a treatable entity and development of a clinical study to delay conversion from mild cognitive impairment to AD. * Completion of a placebo-controlled, multi-center outpatient study of agitation in AD patients including two drug arms and one behavioral management arm. * Completion of a number of studies with enormous scientific and public health impact, including studies demonstrating the lack of benefit associated with the use of estrogen, non-steroidal anti-inflammatory drugs, B vitamins and a statin drug for the treatment of AD. * Widespread sharing of assessment tools, trial methods and data with academic investigators and commercial entities around the world. Provision of infrastructure support to other federally funded clinical efforts, including the Alzheimer's Disease Neuroimaging Initiative. Data Sharing<br /> ADCS is currently finalizing its procedures for data sharing. It is our goal to make the greatest possible use of all data generated by our studies.<br /> Instruments<br /> A mandate of the ADCS is to develop optimal assessment instruments for use in clinical trials. Virtually every current AD trial uses one or more instruments developed by the ADCS. We have experience with a variety of instruments that measure cognitive, functional, global, resource use, and quality of life status. Since 1996 these instruments have been requested by over 500 academic or commercial entities. The instruments most frequently requested are the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-cog), Activities of Daily Living (ADL), and the Clinical Global Impression of Change Scale (CGIC). Some are also available in Spanish and alternative versions. Licensing, copyright and/or permission for use rules may apply.<br /> ADCS Biospecimen Repository<br /> The ADCS laboratory at UCSD banks human tissues from ADCS clinical trials including human tissue, blood, plasma, DNA, urine and CSF. ADCS investigators requesting human tissue, blood or plasma are not required to complete a material transfer agreement (MTA) if they are requesting samples that were collected during clinical trials they directly participated in for research related to the trial. Requests for DNA, urine or CSF require MTAs regardless of participation. Non-ADCS Investigators are required to complete an MTA for all tissue requests.<br /> ADCS Request for Preliminary Proposals<br /> The Alzheimer's Disease Cooperative Study (ADCS) requests preliminary proposals for therapeutic trials to be conducted by the ADCS with potential funding from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH). Proposals may be submitted by academic investigators and/or companies interested in the development of new therapies for AD. Longitudinal collection:<br /> CSF: Annually for 5 years<br /> Plasma/blood: Annually for 5 years<br /> DNA: once<br /> Imaging: every 6 months for 5 years<br /> ng: every 6 months for 5 years<br />
ExampleImage ADCS.PNG +
Has default formThis property is a special property in this wiki. Resource  +
Has role Disease-related portal +, Biomaterial supply resource +, Tissue bank +, Assessment test provider +
Id nif-0000-22434  +
Is part of University of California at San Diego; California; USA +
Keywords Drug +, Alzheimers disease +, Cognitive assessment +, Behavioral assessment +, Blood +, Clinical trial +, Dementia +, DNA +, Human +, News +, Plasma +, Prevention +, Urine +, Cerebral Spinal Fluid +, Image +, Data sharing +, Tissue +, Cognition +, Behavior +
Label Resource:Alzheimers Disease Cooperative Study  +
Listedby Resource:One Mind Biospecimen Bank Listing +, Biobank +
Modification dateThis property is a special property in this wiki. 6 March 2015 00:02:19  +
ModifiedDate 6 March 2015  +
Page has default formThis property is a special property in this wiki. Resource  +
Related disease Alzheimers disease +, Dementia +, Aging +
Species Human +
SuperCategory Resource  +
Supporting Agency National Institute on Aging +
Categories Resource
hide properties that link here 
  No properties link to this page.


Enter the name of the page to start browsing from.

*Note: Neurolex imports many terms and their ids from existing community ontologies, e.g., the Gene Ontology. Neurolex, however, is a dynamic site and any content beyond the identifier should not be presumed to reflect the content or views of the source ontology. Users should consult with the authoritative source for each ontology for current information.